Quarterly Results
RDY Earnings Forecast
Looking ahead, RDY remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2026/Q3 project quarter revenue of 84.67B and an EPS of 18.23.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2026 have been Revise Downward by -0.57%, while EPS estimates have been Revise Downward by -3.64%. For the upcoming Q3 2026, revenue estimates have been adjusted Revise Downward by -0.16% . These revisions correlate with a -6.56% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in RDY long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
1Y
3Y
5Y
Currency: USD
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price0
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Al Analysis
Earnings Surprise Analysis
Revenue
EPS
1Y
3Y
Al Analysis
Earnings Reaction
The chart below shows how RDY performed 10 days before and after its earnings report, based on data from the past quarters. Typically, RDY sees a +0.78% change in stock price 10 days leading up to the earnings, and a +1.18% change 10 days following the report. On the earnings day itself, the stock moves by -1.31%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in JUN/2024, the stock changed -1.58% on the day following the earnings release and then changed by 0.38% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
People Also Watch
Frequently Asked Questions
What were the key highlights of RDY's latest earnings report for FY2025Q1?
RDY reported its FY2025Q1 earnings on 2024-07-27, showcasing a revenue of 76.73B against an estimate of 72.71B, resulting in a 5.52% surprise. The EPS was 1, surpassing the expected 1.1 by -9.09% . The stock experienced a 0.47% price change on the earnings day and a 5.16% change over the next five days, reflecting market reactions to the results.
How did RDY's stock price react after the FY2025Q1 earnings release?
Following RDY's FY2025Q1 earnings announcement on 2024-07-27, the stock price moved by 0.47% on the day of the release. Over the subsequent five days, it saw a 5.16% change. Historically, RDY's stock price tends to shift by an average of +0.78% in the 10 days leading up to earnings and +1.18% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for RDY for 2026/Q3?
For 2026/Q3, analysts estimate RDY’s annual revenue to reach 84.67B, while the EPS is projected at 18.23. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -0.57% and EPS estimates Revise Downward by -0.16% over the past three months, indicating analyst expectation in the company’s performance.
How does RDY's stock price correlate with earnings forecast revisions?
The correlation between RDY's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were Revise Downward by -0.57%, while EPS estimates moved Revise Downward by -0.16% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from RDY's next earnings report?
Based on historical trends, RDY's stock price typically moves by +0.78% in the 10 days before its earnings and +1.18% in the 10 days after. For the upcoming 2026/Q3 earnings, analysts expect an EPS of 18.23 and revenue of 84.67B.
What is the sentiment in Dr Reddy's Laboratories Ltd (RDY) Q2 2026 Earnings Call Summary?
The earnings call reveals mixed aspects: stable financial health with strategic R&D investments and promising biosimilar launches, but concerns over competitive pressures and legal challenges. Strong growth in India and emerging markets is positive, but price erosion in the U.S. and unclear guidance on semaglutide pricing impact sentiments. Given these balanced positives and negatives, a neutral stock reaction is expected.
